GALAD outperforms aMAP and ALBI for predicting HCC in patients with compensated advanced chronic liver disease: A 12-year prospective study.

Hepatol Commun · 2023 · PMC10503687 · PMID 37708455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

In the multivariate model against the other scores, the GALAD score was reconfirmed as a better predictor at each time point ( p = 0.003, p < 0.0001, and p = 0.001, respectively) while the other scores were completely outperformed, with only ALBI showing a borderline significance at 10 years.

also in 7,017 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.